Sugi Predict

Sugi Predict / Compounds / SCHEMBL182929

SCHEMBL182929

SCHEMBL182929

CCOc1ccc(B2OC(C)(C)C(C)(C)O2)cc1OC

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ TSHR P16473 1/20 0.44
▸ LPL P06858 7/20 0.44
▸ LIPG Q9Y5X9 7/20 0.44
▸ MAPK1 P28482 2/20 0.43
▸ CSF1R P07333 1/20 0.43
▸ CALM1 P0DP23 2/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.40
▸ EGFR P00533 1/20 0.40
▸ IGF1R P08069 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16428161 0.94 LPL (0.44) KDM4EGAAMAPTLPLLIPG
SCHEMBL182626 0.92 LPL (0.47) KDM4EGAAMAPTLPLLIPG
SCHEMBL1877988 0.87 CSF1R (0.48) LPLLIPGCSF1R
SCHEMBL25203373 0.87 CSF1R (0.48) LPLLIPGCSF1R
SCHEMBL183050 0.85 CSF1R (0.41) MAPTLPLLIPGMAPK1CSF1R
SCHEMBL20562815 0.84 MEN1 (0.42) GAAMAPTTSHRLPLLIPG
SCHEMBL19747816 0.83 ALDH1A1 (0.55) GAAMAPTTSHRCSF1RALDH1A1
SCHEMBL22408211 0.83 ALDH1A1 (0.53) KDM4EMAPTLPLLIPGMAPK1
SCHEMBL18252684 0.83 LPL (0.45) LPLLIPGCSF1R
SCHEMBL16426769 0.83 CSF1R (0.40) KDM4EGAAMAPTLPLLIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3861001-B1 BORON CONTAINING PDE4 INHIBITORS PFIZER (US) 2023-12-13 — — EP disclosed
EP-3861001-B1 BORON CONTAINING PDE4 INHIBITORS PFIZER (US) 2023-12-13 — — EP disclosed
US-20230148402-A1 Boron Containing PDE4 Inhibitors PFIZER INC. (US) 2023-05-11 — — US disclosed
US-20230148402-A1 Boron Containing PDE4 Inhibitors PFIZER INC. (US) 2023-05-11 — — US disclosed
US-11559538-B2 Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors PFIZER INC. (US) 2023-01-24 — — US disclosed
US-20220002277-A1 PYRIDONE DERIVATIVE HAVING TETRAHYDROPYRANYLMETHYL GROUP DAIICHI SANKYO COMPANY, LIMITED (JP) 2022-01-06 — — US disclosed
US-11208403-B2 Pyridone derivatives having tetrahydropyranylmethyl groups DAIICHI SANKYO COMPANY, LIMITED (JP) 2021-12-28 — — US disclosed
EP-3743420-B1 HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA PLC (GB) 2021-12-15 — — EP disclosed
US-10946031-B2 PDE4 inhibitor (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol PFIZER INC. (US) 2021-03-16 — — US disclosed
US-20210069219-A1 Boron Containing PDE4 Inhibitors PFIZER INC. (US) 2021-03-11 — — US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 — — US disclosed
EP-2438064-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES Novartis AG (CH) 2012-04-11 — — EP disclosed
EP-2049502-B1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-04 — — EP disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 — — US disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 — — US disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 — — US disclosed
WO-2010139731-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2010-12-09 — — WO disclosed
US-20090258882-A1 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors NOVARTIS AG 2009-10-15 — — US disclosed
EP-2049502-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS Novartis AG (CH) 2009-04-22 — — EP disclosed
WO-2008012326-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11559538-B2 Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors PDE4B, PDE4A, PDE3B KDM4E 406/4885GAA 208/4885MAPT 3874/4885
US-20220002277-A1 PYRIDONE DERIVATIVE HAVING TETRAHYDROPYRANYLMETHYL GROUP AXL, TYRO3, LCK KDM4E 2451/4885GAA 2412/4885MAPT 2529/4885
US-20210069219-A1 Boron Containing PDE4 Inhibitors PDE4B, PDE4A, PDE3B KDM4E 406/4885GAA 78/4885MAPT 3172/4885
US-20090258882-A1 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors PDPK1, PI4KA, PIK3CA KDM4E 1674/4885GAA 1153/4885MAPT 4105/4885
US-20230148402-A1 Boron Containing PDE4 Inhibitors PDE4B, PDE4A, PDE3B KDM4E 406/4885GAA 78/4885MAPT 3172/4885
US-11208403-B2 Pyridone derivatives having tetrahydropyranylmethyl groups AXL, TYRO3, PDXK KDM4E 2945/4885GAA 1735/4885MAPT 2654/4885
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 KDM4E 1280/4885GAA 1201/4885MAPT 1751/4885
US-10946031-B2 PDE4 inhibitor (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol PDE4A, PDE4B, PDE12 KDM4E 238/4885GAA 1097/4885MAPT 2689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.